Type 1 Diabetes Fellows Series

April 17, 2024

Application Period Is Now Closed

The application for the 11th annual installment of Endocrine Society’s Type 1 Diabetes Fellows series is now closed. Applicants will receive notifications and more details by no later than mid-March. Fellows that are invited to attend the in-person meeting will receive a promotional code for complimentary registration to ENDO 2024, as well as a travel stipend. To avoid any issues, we kindly request that applicants refrain from registering for the conference until after they have heard back about their application. Non-accepted applicants will be provided a promo code. 

Have questions? Please contact education@endocrine.org for assistance. 

As in years past, the Type 1 Diabetes Fellows Program will have two core components:  

  • On-demand didactic sessions; and 
  • A prestigious, in-person meeting held in Boston, MA, May 30-31, ahead of ENDO, where fellows get the exclusive opportunity to meet with experts in T1D and product demonstrations with industry representatives.  

Travel Visas

All individuals traveling from outside the United States must apply for entry visas as soon as possible and at least four months prior to the date of travel for ENDO 2024. The most updated information may be found at the U.S. State Department website. Scientists visiting the U.S. may find helpful information at The National Academies of Sciences website. Visa appointment wait times can be found here.  

Please do not wait until to hear about your application or until ENDO 2024 registration opens in January 2024 before applying for a visa. All visitors traveling to the U.S. from visa waiver countries (i.e., Europe, Japan, Australia, etc.) must meet all requirements. If you need more information on the Electronic System for Travel Authorization (ESTA) or a list of visa waiver countries, click here. For information on the anticipated timeline, please visit the State Department website.

Please contact meetings@endocrine.org to request a visa invitation letter. 

2024 Program Agenda

Thursday, May 30, 2024

 6:00-6:30 PM            

 Welcome Reception 

 6:30-7:00 PM

 Dinner

 7:00-7:45 PM

Keynote Address: Innovations in Insulin Therapy
Irl B. Hirsch, MD, University of Washington

 7:45-8:00 PM

 Q&A

 8:00-9:00 PM

 Product Showcase


Friday, May 31, 2024

7:00-8:00 AM             

Registration and Breakfast with the Faculty 

 8:00-8:15 AM

Welcoming Remarks
Rodolfo J. Galindo, MD, University of Miami

 8:15-10:30 AM

Diabetes Technology

 

CGM Use and Interpretation with MDI

Viral Shah, MD, Indiana University School of Medicine

CGM Use and Interpretation with Open Loop
Georgia Davis, MD, Emory University School of Medicine

CGM Use and Interpretation with Closed Loop
Grazia Aleppo, MD, Northwestern University 

10:30-11:00 AM

Break & Questions for Industry Representatives  

 11:00 AM-12:00 PM

Small Group Discussions

T1D and Technology in the Older Individual
Medha Munsi, MD, Harvard Medical School

Sick Day
Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital

Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes
Amy Hess Fischl, MS RDN BC-ADM CDCES, University of Chicago

Type 1 Diabetes in Pregnancy: Before, During, and After
Camille Powe, MD, Massachusetts General Hospital

In-Patient Management
Guillermo E. Umpierrez, MD, CDCES, FACE, MACP, Emory University School of Medicine

Discussing Pump Therap
Grazia Aleppo, MD, Northwestern University

Billing
Carol Wysham, MD, Rockwood Clinic PS

 12:00-1:00 PM

Lunch Discussion with Faculty

 1:00-1:45 PM

Obesity and T1D
Eden Miller, DO, Rocky Mountain Diabetes and Osteoporosis Center

 1:45-2:30 PM  

Novel Immune Therapy
Desmond A. Schatz, MD, University of Florida College of Medicine

 2:30-3:00 PM

Break & Questions for Industry Representatives

3:00-4:00 PM

Small Group Discussions

T1D and Technology in the Older Individual
Medha Munsi, MD, Harvard Medical School

Sick Day
Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital

Implementing Realistic Nutrition Therapy for People with Type 1 Diabetes
Amy Hess Fischl, MS RDN BC-ADM CDCES, University of Chicago

Type 1 Diabetes in Pregnancy: Before, During, and After
Camille Powe, MD, Massachusetts General Hospital

In-Patient Management

Guillermo E. Umpierrez, MD, CDCES, FACE, MACP, Emory University School of Medicine

Discussing Pump Therapy
Grazia Aleppo, MD, Northwestern University

Billing
Carol Wysham, MD, Rockwood Clinic PS

 4:00-4:45 PM

Fresh Look at Insulin
Dr. Bernard Zinman, FRCP, FACP, MD, Mount Sinai Hosp, University of Toronto

 4:45-5:00 PM

Closing Comments
Rodolfo J. Galindo, MD, University of Miami

 

 


To Be Released on the Center for Learning

  • T1D in Underserved Populations: Lorena Wright, MD, University of Washington School of Medicine
  • The Pathogenesis of T1D: The Future for Preserving Beta Cell Function: Mark Atkinson, PhD, University of Florida
  • Applying New Billing Rules to Outpatient Diabetes Care: Carol Wysham, MD, Rockwood Clinic PS
  • Stages of Diabetes:  Carla J. Greenbaum, MD, Benaroya Research Institute
  • Preparing for Future Careers in Endocrinology: What I Wish I was Told When I Left my Fellowship: Luisa Duran, MD, John Muir Health
  • Newly Diagnosed of Type 1 Diabetes: Irl B. Hirsch, MD, University of Washington
  • Hypoglycemia in T1D: Risks and Practical Prevention Strategies: Elizabeth Seaquist, MD, University of Minnesota
  • T1D and the Prevention and Treatment of Macrovascular Disease: Robert H. Eckel, MD, University of Colorado
  • The Endocrinologist’s Role in Screening and Managing Microvascular Disease: Janet McGill, MD, MA, FACE, Washington University in St. Louis
  • Identifying and Confronting Challenging Transitions: Faisal S. Malik, MD, MSHS, Seattle Children’s Hospital
  • Developmental Considerations for Youth with T1D and Their Families: Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University
  • Type 1 Diabetes in Pregnancy: Before, During, and After: Camille Powe, MD, Massachusetts General Hospital
  • Adjunctive Therapies for T1D: Anne Peters, MD, USC Westside Center for Diabetes 

Learning Objectives

Upon successful completion these educational initiatives, participants should be better able to:

  • Discuss the prevalence and progression of type 1 diabetes to recognize signs and differentially diagnose diabetes
  • Devise individualized treatment strategies that use new and emerging insulin therapies to manage individuals with type 1 diabetes with and without common comorbid conditions.
  • Incorporate diabetes technologies, including insulin pump therapy and continuous glucose monitoring, into treatment strategies for appropriate individuals with type 1 diabetes and evaluate data from those technologies.
  • Recognize and evaluate individuals with type 1 diabetes for signs of depression and distress using updated guidelines and practice tools.
  • Apply updated knowledge of treatments, practice guidelines, and clinical skills to improve care, long-term outcomes, and sick day management of individuals with type 1 diabetes.
  • Describe current and emerging therapy for the treatment of pre-clinical type 1 diabetes
  • Discuss various strategies for exercise and minimizing hypoglycemia for individuals with T1D
Last Updated:
Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.